RION engages Lonza to scale manufacturing exosome based therapeutics

RION, a commercial and clinical-stage regenerative medicine company pioneering platelet-derived exosomes for both human and animal…

NeuroEM Therapeutics Closes Initial Rounds in $5 Million Equity Raise to Commercialize Drug-free Alzheimer’s Treatment

Jun 132025 NeuroEM Therapeutics Closes Initial Rounds in $5 Million Equity Raise to Commercialize Drug-free Alzheimer’s…

PhoreMost makes key appointments to Board to advance development of next-generation degrader therapeutics

PhoreMost Ltd., a next-generation targeted protein degradation (TPD) company progressing a pipeline of degrader therapeutics within…